Telix Pharmaceuticals (TLX) shares surged after the FDA accepted its NDA for TLX101-Px, a brain cancer imaging agent. The drug helps distinguish tumor recurrence from treatment effects, with a PDUFA date of September 11, 2026. Despite this milestone, the company excluded revenue from this agent in its FY26 guidance.